South Korean preclinical biotechnology company developing immune-modulating therapies, including regulatory T-cell therapies and biologics for autoimmune disease, graft-versus-host disease, and cancer
South Korean preclinical biotechnology company developing immune-modulating therapies, including regulatory T-cell therapies and biologics for autoimmune disease, graft-versus-host disease, and cancer. Its reported pipeline includes CAR-Treg and Treg cell therapy, exosomes, monoclonal antibodies, and Fc-fusion proteins; PB-203 targets PD-L1 and placental growth factor (PlGF) for pancreatic cancer.